Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
172.24
+0.04 (+0.02%)
4:00:00 PM EDT: $172.17 -0.07 (-0.04%)
Products, Strategic Combinations

Vor Biopharma Announces Collaboration With Janssen To Develop Treatment For Acute Myeloid Leukemia (Aml)

Published: 07/08/2021 12:22 GMT
Johnson & Johnson (JNJ) - Vor Biopharma Announces Collaboration With Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-specific Antibody Therapy for Acute Myeloid Leukemia (aml).
Vor Biopharma Inc - Under Terms of Collaboration, Vor Biopharma Will Investigate Combination of These Two Technologies Into a Treatment Solution.
Vor Biopharma Inc - Collaboration Agreement Provides That Each Company Retains All Rights and Ownership to Their Respective Programs and Platforms.